KRAS Mutations Reprogram RNA m6A Modifications to Drive CD73-Dependent Immune Evasion in Colorectal Cancer.

KRAS mutations in colorectal cancer increase m6A modifications on CD73 mRNA, promoting immune evasion and tumor growth.

• Why it matters: Understanding how KRAS mutations contribute to immune suppression can identify new therapeutic targets to improve immunotherapy responses in CRC.
• What they did: Researchers used methylated RNA immunoprecipitation sequencing to show that KRAS-mutant cells have increased m6A on CD73 mRNA, mediated by TEAD4 and METTL3, and tested METTL3 knockdown effects in tumor models.
• The result: METTL3 inhibition reduced tumor growth, enhanced immune cell infiltration, and synergized with anti-PD-1 and CD73 inhibitors, suggesting METTL3 as a promising target to counteract KRAS-driven immune evasion.